IN2013DN02552A - - Google Patents

Download PDF

Info

Publication number
IN2013DN02552A
IN2013DN02552A IN2552DEN2013A IN2013DN02552A IN 2013DN02552 A IN2013DN02552 A IN 2013DN02552A IN 2552DEN2013 A IN2552DEN2013 A IN 2552DEN2013A IN 2013DN02552 A IN2013DN02552 A IN 2013DN02552A
Authority
IN
India
Prior art keywords
ht2c
benzazepine
tetrahydro
chloro
salts
Prior art date
Application number
Inventor
Anthony C Blackburn
Scott Stirn
Yun Shan
Anna Shifrina
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IN2013DN02552A publication Critical patent/IN2013DN02552A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Salts of the 5-HT2c-receptor agonist (i?)-8-chloro-l-methyl-2,3 ,4,5-tetrahydro-ii/-3-benzazepine, and dosage forms comprising them that are useful for, inter Alia, weight management.
IN2552DEN2013 2010-09-01 2011-08-31 IN2013DN02552A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40258910P 2010-09-01 2010-09-01
PCT/US2011/049953 WO2012030951A1 (en) 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists

Publications (1)

Publication Number Publication Date
IN2013DN02552A true IN2013DN02552A (en) 2015-08-07

Family

ID=44645827

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2552DEN2013 IN2013DN02552A (en) 2010-09-01 2011-08-31

Country Status (11)

Country Link
US (1) US20140148442A1 (en)
EP (1) EP2611781A1 (en)
JP (1) JP2013536858A (en)
KR (1) KR20130138768A (en)
CN (1) CN103189358A (en)
AU (1) AU2011296027A1 (en)
CA (1) CA2808900A1 (en)
IN (1) IN2013DN02552A (en)
MX (1) MX2013002430A (en)
SG (2) SG188363A1 (en)
WO (1) WO2012030951A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189053A (en) 2010-09-01 2013-07-03 艾尼纳制药公司 Modified-release dosage forms of 5-ht2c agonists useful for weight management
MX2013002422A (en) 2010-09-01 2013-05-17 Arena Pharm Inc Salts of lorcaserin with optically active acids.
WO2012030957A2 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
MX2013002418A (en) 2010-09-01 2013-08-01 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment.
MY181736A (en) 2012-10-09 2021-01-05 Arena Pharm Inc Method of weight management
WO2014135545A1 (en) * 2013-03-05 2014-09-12 Sandoz Ag Solid dispersion comprising amorphous lorcaserin hydrochloride
WO2014187768A1 (en) * 2013-05-20 2014-11-27 Lek Pharmaceuticals D.D. Novel synthetic processes to 8-chloro-3-benzo[d]azepine via friedel-crafts alkylation of olefin
EP2868656A1 (en) * 2013-11-05 2015-05-06 LEK Pharmaceuticals d.d. Stabilized amorphous lorcaserin hydrochloride
WO2015096119A1 (en) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 Lorcaserin salts and crystals thereof, preparation methods and uses thereof
US9981912B2 (en) 2014-04-21 2018-05-29 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
CN103901151A (en) * 2014-04-23 2014-07-02 湖北朗昕生化药业有限公司 Method for detecting content of lorcaserin hydrochloride through high performance liquid chromatography (HPLC) method
WO2016069875A1 (en) 2014-10-30 2016-05-06 Arena Pharmaceuticals, Inc. Compositions and methods for ceasing tobacco smoking
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561916B1 (en) 1984-03-30 1987-12-11 Lafon Labor GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
PT100602A (en) * 1991-06-21 1993-09-30 Smithkline Beecham Plc USE OF TETRA-HYDROBENZAZEPIN DERIVATIVES, TETRA-HYDROBENZAZEPINES DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69331839T2 (en) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Fast-dissolving tablet and its manufacture
DE4203932A1 (en) 1992-02-11 1993-08-12 Deutsche Aerospace SEND / RECEIVE MODULE
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
ATE208615T1 (en) 1993-07-09 2001-11-15 Scherer Corp R P METHOD FOR PRODUCING FREEZE-DRIED MEDICINAL DOSAGE FORMS
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
EP1425577A4 (en) * 2001-08-10 2004-12-29 Symyx Technologies Inc Apparatuses and methods for creating and testing pre-formulations and systems for same
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
WO2005003096A1 (en) * 2003-06-17 2005-01-13 Arena Pharmaceuticals, Inc. Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
ES2571220T3 (en) * 2003-06-17 2016-05-24 Arena Pharm Inc 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US8022062B2 (en) * 2004-02-25 2011-09-20 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
US8168624B2 (en) * 2004-12-21 2012-05-01 Arena Pharmaceuticals, Inc. Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
CN102627607A (en) 2004-12-23 2012-08-08 艾尼纳制药公司 5HT2c receptor modulator compositions and methods of use
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JP5165568B2 (en) * 2005-09-01 2013-03-21 イーライ リリー アンド カンパニー 6-Substituted-2,3,4,5-tetrahydro-1H-benzo [d] azepine as 5-HT2C receptor agonist
ATE437859T1 (en) * 2005-09-01 2009-08-15 Lilly Co Eli 6-SUBSTITUTED-2,3,4,5-TETRAHYDRO-1H-BENZOEDUEAZEPINES AS 5-HT2C RECEPTOR AGONISTS
CA2646044A1 (en) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
SG177128A1 (en) * 2006-12-05 2012-01-30 Arena Pharm Inc Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
PT2114933E (en) 2007-01-04 2011-12-20 Prosidion Ltd Piperidine gpcr agonists
WO2009051747A1 (en) * 2007-10-15 2009-04-23 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
US8822727B2 (en) 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CA2719507C (en) 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
EP2303859A4 (en) 2008-06-20 2012-08-22 Metabolex Inc Aryl gpr119 agonists and uses thereof
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
AR077215A1 (en) 2009-06-24 2011-08-10 Boehringer Ingelheim Int PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED TO THEM

Also Published As

Publication number Publication date
KR20130138768A (en) 2013-12-19
MX2013002430A (en) 2013-07-22
JP2013536858A (en) 2013-09-26
WO2012030951A1 (en) 2012-03-08
AU2011296027A1 (en) 2013-04-04
CN103189358A (en) 2013-07-03
SG188363A1 (en) 2013-04-30
SG10201506873WA (en) 2015-10-29
CA2808900A1 (en) 2012-03-08
US20140148442A1 (en) 2014-05-29
EP2611781A1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
IN2013DN02552A (en)
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
MY181898A (en) Heterocyclic compounds and uses thereof
MX2019010602A (en) Cdk inhibitors.
GB201017345D0 (en) Receptor antagonists
MX355728B (en) Kinase inhibitors.
RS53818B1 (en) Pyrrolobenzodiazepines and conjugates thereof
UY34763A (en) INHIBITORS OF THE PLAQUETARY AGGREGATION
UY34559A (en) BROMODOMINIUM INHIBITORS
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2012DN06714A (en)
MX2013002422A (en) Salts of lorcaserin with optically active acids.
MX2013008390A (en) Preparation of metal-triazolate frameworks.
UY34216A (en) New compounds that inhibit the activity of Lp-PLA2
TW201144301A (en) Processes for preparing linezolid
MA34075B1 (en) A pharmaceutical composition containing pyrimidine derivatives
MX2013002421A (en) Non-hygroscopic salts of 5-ht2c agonists.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
IN2014DN11078A (en)
PH12015501390A1 (en) Tablets with improved acceptance and good storage stability
IT1400702B1 (en) EQUIPMENT FOR PACKING LOADS WITH THERMORETABLE FILM, EQUIPPED WITH ADJUSTABLE BURNERS.
UA51902U (en) use of interleukin-1 receptor antagonists (aryl-1) as frigoprotective agent
UA54879U (en) Use of antagonist of interleukin-1 receptor as antioxidant agent
UA56040U (en) 1,3-dimethyl-7-n-chlorobenzene-8-n-bromobenzylidene hydrazinoxanthine exhibiting diuretic and anti-oxidant action